Baxter International Inc (BAX) : Murphy Pohlad Asset Management scooped up 5,035 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 13, 2016. The investment management firm now holds a total of 61,291 shares of Baxter International Inc which is valued at $2,869,645.Baxter International Inc makes up approximately 2.08% of Murphy Pohlad Asset Management’s portfolio.
Other Hedge Funds, Including , Loring Wolcott Coolidge Fiduciary Advisors Llpma boosted its stake in BAX in the latest quarter, The investment management firm added 213 additional shares and now holds a total of 1,713 shares of Baxter International Inc which is valued at $80,203.Searle reduced its stake in BAX by selling 26,600 shares or 84.18% in the most recent quarter. The Hedge Fund company now holds 5,000 shares of BAX which is valued at $234,100. Baxter International Inc makes up approx 2.32% of Searle’s portfolio.Stillwater Investment Management boosted its stake in BAX in the latest quarter, The investment management firm added 611 additional shares and now holds a total of 19,379 shares of Baxter International Inc which is valued at $904,030. Baxter International Inc makes up approx 0.51% of Stillwater Investment Management’s portfolio.Cohen Lawrence B reduced its stake in BAX by selling 1,850 shares or 22.77% in the most recent quarter. The Hedge Fund company now holds 6,275 shares of BAX which is valued at $292,729. Baxter International Inc makes up approx 0.17% of Cohen Lawrence B’s portfolio.
Baxter International Inc closed down -0.22 points or -0.47% at $46.55 with 28,11,905 shares getting traded on Monday. Post opening the session at $46.81, the shares hit an intraday low of $46.34 and an intraday high of $46.86 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.